New insider activity at Guardant Health ( (GH) ) has taken place on June 20, 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
In recent transactions involving Guardant Health stock, Director Tariq Musa sold 3,213 shares, amounting to a total of $158,947. Additionally, Director Ian Clark sold 6,672 shares, with the sale valued at $322,791.
Recent Updates on GH stock
Guardant Health has experienced notable developments in the past 24 hours, with significant attention drawn to its Shield multi-cancer detection test receiving Breakthrough Device designation from the FDA. This designation is expected to enhance the company’s growth prospects by facilitating the test’s development and regulatory review process. Additionally, Cathie Wood’s ARK Investment has made substantial purchases of Guardant Health shares, indicating confidence in the company’s strategic advancements and innovative growth potential. Despite these positive developments, analysts have expressed concerns over Guardant Health’s financial performance, citing high leverage and cash flow issues, which continue to impact its valuation. Nonetheless, the company’s strong revenue growth and favorable technical indicators provide some support to its stock performance.
Spark’s Take on GH Stock
According to Spark, TipRanks’ AI Analyst, GH is a Neutral.
Guardant Health’s overall stock score is primarily impacted by its financial performance challenges, including high leverage and cash flow issues, despite strong revenue growth. Positive technical indicators and a favorable earnings call provide some support, but valuation concerns remain due to ongoing losses.
To see Spark’s full report on GH stock, click here.
More about Guardant Health
YTD Price Performance: 59.18%
Average Trading Volume: 2,198,345
Technical Sentiment Signal: Buy
Current Market Cap: $6.27B